- Conditions
- End Stage Renal Disease, Hypertension, Extracellular Volume Overload, Intradialytic Hypotension
- Interventions
- IBPS-Guided Ultrafiltration
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Condition Directory
Hypertension clinical trials
Directory of U.S. ClinicalTrials.gov public records for Hypertension. Browse Hypertension recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 1, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
456
Shown on this page
12
Current sort
Recently updated
Condition scope
Hypertension
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Hypertension studies are organized in the registry
“Hypertension” searches also surface pulmonary hypertension — a different disease with its own research community — so watch for “pulmonary” in titles when scanning results. The blood-pressure portfolio itself includes a high share of behavioral, dietary, and device studies alongside medication trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 456 matching trials for Hypertension.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Interventions
- NS-863 Low Dose, NS-863 High Dose, Placebo
- Drug · Other
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Insulin Resistance, Obesity, Diabetes, Hypertension, Dyslipidemias, Metabolic Syndrome
- Interventions
- Diet Counseling, Exercise Counseling
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hypertension, Pulmonary, Lung Diseases, Interstitial
- Interventions
- TX000045
- Drug
- Lead sponsor
- Tectonic Operating Company, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • San Francisco, California • Boise, Idaho + 1 more
- Conditions
- Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
- Interventions
- AZD3427, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- REGN13335, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Omaha, Nebraska + 1 more
- Conditions
- Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Sarcoidosis Associated Pulmonary Hypertension
- Interventions
- Placebo, LAM-001
- Drug
- Lead sponsor
- IRulya Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Arterial Hypertension, Insulin Resistance
- Interventions
- Nutrition and Exercise
- Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypertension
- Interventions
- Telemedicine management of Hypertension, Usual Care
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Interventions
- Paradise Ultrasound Renal Denervation Treatment
- Device
- Lead sponsor
- ReCor Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Long Beach, California • Los Angeles, California • Sacramento, California + 39 more
- Conditions
- Hypertension, Dyslipidemia, Diabetes Mellitus, Obesity, Cardiovascular Disease
- Interventions
- Experimental - 12 Week P3-EX Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants, Active Control - 12 Week ACSM-PAVS Unsupervised Exercise Program with Virtual Weekly Oversight from Graduate Research Assistants
- Behavioral
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- Farmington, Connecticut • Hartford, Connecticut • Storrs, Connecticut
About this Hypertension clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Hypertension as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Hypertension.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Hypertension.